Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 11/20 | 0.70 |
| ▸ | AKR1C2 | P52895 | 11/20 | 0.70 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.54 |
| ▸ | ACLY | P53396 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | GFER | P55789 | 1/20 | 0.49 |
| ▸ | NGLY1 | Q96IV0 | 1/20 | 0.49 |
| ▸ | FABP4 | P15090 | 1/20 | 0.47 |
| ▸ | MPO | P05164 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | KCNK2 | O95069 | 1/20 | 0.46 |
| ▸ | KCNK10 | P57789 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9709047 | 0.91 | AKR1C3 (0.60) | AKR1C3AKR1C2GRIK1ACLYMAPT | |
| SCHEMBL13890899 | 0.90 | AKR1C3 (0.59) | AKR1C3AKR1C2GRIK1ACLYMAPT | |
| SCHEMBL1415595 | 0.89 | AKR1C3 (0.67) | AKR1C3AKR1C2GRIK1MAPTGFER | |
| SCHEMBL4158603 | 0.82 | FABP4 (0.71) | AKR1C3AKR1C2MAPTFABP4 | |
| SCHEMBL11604475 | 0.81 | AKR1C3 (0.62) | AKR1C3AKR1C2ACLYMAPTFABP4 | |
| SCHEMBL9942872 | 0.79 | ACLY (0.55) | AKR1C3AKR1C2GRIK1ACLYMAPT | |
| SCHEMBL16632333 | 0.78 | ACLY (0.54) | AKR1C3AKR1C2GRIK1ACLYKDM4E | |
| SCHEMBL4152400 | 0.78 | ACLY (0.54) | AKR1C3AKR1C2GRIK1ACLYMAPT | |
| Hydrochloric Acid SCHEMBL145407 | 0.76 | ACLY (0.53) | AKR1C3AKR1C2GRIK1ACLYKDM4E | |
| SCHEMBL28472949 | 0.76 | AKR1C3 (0.64) | AKR1C3AKR1C2MAPTGFERNGLY1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9150554-B2 | Fused ring inhibitors of hepatitis C | PRESIDIO PHARMACEUTICALS, INC. (US) | 2015-10-06 | — | — | US | disclosed |
| US-9150554-B2 | Fused ring inhibitors of hepatitis C | PRESIDIO PHARMACEUTICALS, INC. (US) | 2015-10-06 | — | — | US | disclosed |
| US-8999967-B2 | Tricyclic fused ring inhibitors of hepatitis C | PRESIDIO PHARMACEUTICALS, INC. (US) | 2015-04-07 | — | — | US | disclosed |
| US-8999967-B2 | Tricyclic fused ring inhibitors of hepatitis C | PRESIDIO PHARMACEUTICALS, INC. (US) | 2015-04-07 | — | — | US | disclosed |
| US-20130296304-A1 | TRICYCLIC FUSED RING INHIBITORS OF HEPATITIS C | PRESIDIO PHARMACEUTICALS, INC. (US) | 2013-11-07 | — | — | US | disclosed |
| US-20130296304-A1 | TRICYCLIC FUSED RING INHIBITORS OF HEPATITIS C | PRESIDIO PHARMACEUTICALS, INC. (US) | 2013-11-07 | — | — | US | disclosed |
| US-20120040962-A1 | FUSED RING INHIBITORS OF HEPATITIS C | PRESIDIO PHARMACEUTICALS, INC. (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120040962-A1 | FUSED RING INHIBITORS OF HEPATITIS C | PRESIDIO PHARMACEUTICALS, INC. (US) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130296304-A1 | TRICYCLIC FUSED RING INHIBITORS OF HEPATITIS C | HAVCR2, HCCS, LIPC | AKR1C3 532/4885AKR1C2 1038/4885GRIK1 3972/4885 |
| US-20120040962-A1 | FUSED RING INHIBITORS OF HEPATITIS C | HAVCR2, HCCS, ZC3HAV1 | AKR1C3 968/4885AKR1C2 1452/4885GRIK1 4160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.